• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Gram-Positive Bacterial Infections - Pipeline Review, H2 2013 - Product Image

Gram-Positive Bacterial Infections - Pipeline Review, H2 2013

  • Published: October 2013
  • 189 pages
  • Global Markets Direct

FEATURED COMPANIES

  • AiCuris GmbH & Co. KG
  • Aphios Corporation
  • Cellceutix Corporation
  • Destiny Pharma Ltd.
  • Lytix Biopharma AS
  • Novabiotics Ltd
  • MORE

Gram-Positive Bacterial Infections - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Gram-Positive Bacterial Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Gram-Positive Bacterial Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gram-Positive Bacterial Infections. Gram-Positive Bacterial Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Gram-Positive Bacterial Infections.
- A review READ MORE >

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Gram-Positive Bacterial Infections Overview
Therapeutics Development
An Overview of Pipeline Products for Gram-Positive Bacterial Infections
Gram-Positive Bacterial Infections Therapeutics under Development by Companies
Gram-Positive Bacterial Infections Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Gram-Positive Bacterial Infections Therapeutics - Products under Development by Companies
Gram-Positive Bacterial Infections Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Gram-Positive Bacterial Infections Therapeutics Development
Rib-X Pharmaceuticals, Inc.
Aphios Corporation
BioMarin Pharmaceutical Inc.
Alchemia Limited
Immtech Pharmaceuticals, Inc.
Basilea Pharmaceutica Ltd.
Oragenics, Inc.
Dongwha Pharm Co., Ltd.
Theravance, Inc.
Phynova Group Ltd
Novabiotics Ltd
Priaxon AG
ConjuGon, Inc.
MicuRx Pharmaceuticals, Inc.
AiCuris GmbH & Co. KG
Destiny Pharma Ltd.
Atox Bio Inc.
Microbiotix, Inc.
Cellceutix Corporation
KYORIN Pharmaceutical Co., Ltd.
Lytix Biopharma AS
TAXIS Pharmaceuticals, Inc.
Aureogen Biosciences, Inc.
Cantab Biopharmaceuticals Limited
Gram-Positive Bacterial Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
PYN-6 - Drug Profile
LT-29 - Drug Profile
MX-2401 - Drug Profile
TD-1792 - Drug Profile
Antibiotic Program - Drug Profile
MU-1140 - Drug Profile
RX-04 - Drug Profile
RX-02 - Drug Profile
NVB-333 - Drug Profile
zabofloxacin - Drug Profile
LTX-109 - Drug Profile
Marinus - Drug Profile
AB-103 - Drug Profile
avarofloxacin hydrochloride - Drug Profile
ceftobiprole - Drug Profile
Hybrid Antibiotics - Drug Profile
Antibiotic Program - Drug Profile
SLP-0905 - Drug Profile
SLP-0906 - Drug Profile
SLP-1003 - Drug Profile
SLP-0904 - Drug Profile
SLP-1004 - Drug Profile
BAC Gram -/+ - Drug Profile
KRPAM-1977X - Drug Profile
KRPAM-1977Y - Drug Profile
RX-P792 - Drug Profile
Novarifyn - Drug Profile
Drug For Gram Positive Wound Infections - Drug Profile
MBX-500 - Drug Profile
MU-1140-S - Drug Profile
3-(4-chlorophenyl)-4-Substituted Pyrazole Derivatives - Drug Profile
NAI-107 - Drug Profile
Azachryseniums Series - Drug Profile
XF-70 - Drug Profile
PC-190723 - Drug Profile
PBP-539 - Drug Profile
Thiolactomycin Analogues - Drug Profile
SP-2078 - Drug Profile
Sortase A Enzyme Inhibitor - Drug Profile
Antibacterial Compounds For Gram Possitive Bacterial Infections - Drug Profile
TD-1607 - Drug Profile
Ripostatin - Drug Profile
Drug For Gram-Positive Bacterial Infections - Drug Profile
Broad-Spectrum Antibiotics Targeting Switch Region - Drug Profile
Broad-Spectrum Antibiotics Targeting RNA-Exit-Channel - Drug Profile
VT-02 - Drug Profile
Antibiotic Compounds - Drug Profile
PMX-100 - Drug Profile
PMX-229 - Drug Profile
PMX-519 - Drug Profile
PMX-1091 - Drug Profile
PMX-1142 - Drug Profile
PMX-1241 - Drug Profile
PMX-1442 - Drug Profile
PMX-1445 - Drug Profile
PMX-1555 - Drug Profile
PMX-868 - Drug Profile
PMX-1090 - Drug Profile
PMX-223 - Drug Profile
PMX-225 - Drug Profile
PMX-1363 - Drug Profile
PMX-1405 - Drug Profile
PMX-183 - Drug Profile
NOSO-95 - Drug Profile
NOSO-74 - Drug Profile
Compound-45 - Drug Profile
BMY-28117 - Drug Profile
Gamma AApeptides - Drug Profile
PMX-1099 - Drug Profile
PMX-843 - Drug Profile
PMX-1102 - Drug Profile
PMX-1014 - Drug Profile
PMX-0196 - Drug Profile
PMX-1045 - Drug Profile
PMX-1056 - Drug Profile
PMX-1057 - Drug Profile
PMX-1094 - Drug Profile
PMX-0243 - Drug Profile
PMX-0231 - Drug Profile
PMX-255 - Drug Profile
PMX-520 - Drug Profile
PMX-728 - Drug Profile
PMX-741 - Drug Profile
Broad Spectrum Antimicrobials - Drug Profile
Gram-Positive Bacterial Infections Therapeutics - Drug Profile Updates
Gram-Positive Bacterial Infections Therapeutics - Discontinued Products
Gram-Positive Bacterial Infections Therapeutics - Dormant Products
Gram-Positive Bacterial Infections - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Gram-Positive Bacterial Infections, H2 2013
Products under Development for Gram-Positive Bacterial Infections - Comparative Analysis, H2 2013
Number of Products under Development by Companies, H2 2013
Number of Products under Development by Companies, H2 2013 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2013
Comparative Analysis by Late Stage Development, H2 2013
Comparative Analysis by Mid Clinical Stage Development, H2 2013
Comparative Analysis by Early Clinical Stage Development, H2 2013
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013
Products under Development by Companies, H2 2013
Products under Development by Companies, H2 2013 (Contd..1)
Products under Development by Companies, H2 2013 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2013
Rib-X Pharmaceuticals, Inc., H2 2013
Aphios Corporation, H2 2013
BioMarin Pharmaceutical Inc., H2 2013
Alchemia Limited, H2 2013
Immtech Pharmaceuticals, Inc., H2 2013
Basilea Pharmaceutica Ltd., H2 2013
Oragenics, Inc., H2 2013
Dongwha Pharm Co., Ltd., H2 2013
Theravance, Inc., H2 2013
Phynova Group Ltd, H2 2013
Novabiotics Ltd, H2 2013
Priaxon AG, H2 2013
ConjuGon, Inc., H2 2013
MicuRx Pharmaceuticals, Inc., H2 2013
AiCuris GmbH & Co. KG, H2 2013
Destiny Pharma Ltd., H2 2013
Atox Bio Inc., H2 2013
Microbiotix, Inc., H2 2013
Cellceutix Corporation, H2 2013
KYORIN Pharmaceutical Co., Ltd., H2 2013
Lytix Biopharma AS, H2 2013
TAXIS Pharmaceuticals, Inc., H2 2013
Aureogen Biosciences, Inc., H2 2013
Cantab Biopharmaceuticals Limited, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Combination Products, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Stage and Molecule Type, H2 2013
Gram-Positive Bacterial Infections Therapeutics - Drug Profile Updates
Gram-Positive Bacterial Infections Therapeutics - Discontinued Products
Gram-Positive Bacterial Infections Therapeutics - Dormant Products
Gram-Positive Bacterial Infections Therapeutics - Dormant Products (Contd..1)

List of Figures
Number of Products under Development for Gram-Positive Bacterial Infections, H2 2013
Products under Development for Gram-Positive Bacterial Infections - Comparative Analysis, H2 2013
Products under Development by Companies, H2 2013
Products under Investigation by Universities/Institutes, H2 2013
Late Stage Products, H2 2013
Mid Clinical Stage Products, H2 2013
Early Clinical Stage Products, H2 2013
Discovery and Pre-Clinical Stage Products, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Combination Products, H2 2013
Assessment by Route of Administration, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Molecule Type, H2 2013
Assessment by Stage and Molecule Type, H2 2013 60

Rib-X Pharmaceuticals, Inc.
Aphios Corporation
BioMarin Pharmaceutical Inc.
Alchemia Limited
Immtech Pharmaceuticals, Inc.
Basilea Pharmaceutica Ltd.
Oragenics, Inc.
Dongwha Pharm Co., Ltd.
Theravance, Inc.
Phynova Group Ltd
Novabiotics Ltd
Priaxon AG
ConjuGon, Inc.
MicuRx Pharmaceuticals, Inc.
AiCuris GmbH & Co. KG
Destiny Pharma Ltd.
Atox Bio Inc.
Microbiotix, Inc.
Cellceutix Corporation
KYORIN Pharmaceutical Co., Ltd.
Lytix Biopharma AS
TAXIS Pharmaceuticals, Inc.
Aureogen Biosciences, Inc.
Cantab Biopharmaceuticals Limited

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos